文献速递类风湿关节炎

类风湿关节炎患者COVID-19结局:美国多中心研究网络研究

Outcomes of COVID-19 in patients with rheumatoid arthritis: A multicenter research network study in the United States.
PubMed 文献 · Semin Arthritis Rheum · 2021-08-20

该比较队列研究利用美国多中心研究网络提取2020年1月20日至2021年4月11日期间诊断为COVID-19的成人RA患者及无RA的成人COVID-19患者数据,评估诊断后30天内的COVID-19结局。共纳入9730例RA合并COVID-19患者和656979例非RA的COVID-19患者。匹配前RA组所有结局风险均高于非RA组,匹配后除静脉血栓栓塞症(VTE)和脓毒症外其余结局无差异;男性、黑人种族和糖皮质激素使用增加不良结局风险;利妥昔单抗或IL-6抑制剂使用者住院风险高于TNF抑制剂使用者。

要点

  • 匹配后RA患者VTE和脓毒症风险仍高于非RA,提示RA为独立危险因素。
  • 男性、黑人种族和糖皮质激素使用与RA合并COVID-19不良结局相关。
  • 利妥昔单抗或IL-6抑制剂使用者住院风险高于TNF抑制剂使用者。

核心结论

  • 匹配前RA组所有COVID-19结局风险均高于非RA组,匹配后多数结局无差异,提示风险归因于校正因素。
  • 匹配后RA组VTE和脓毒症风险仍较高,提示RA为独立危险因素。
  • 男性、黑人种族和糖皮质激素使用与RA合并COVID-19不良结局相关。
  • 利妥昔单抗或IL-6抑制剂使用者住院风险高于TNF抑制剂使用者,JAK抑制剂或阿巴西普使用者与TNF抑制剂使用者无显著差异。

研究设计与样本

  • 比较队列研究,使用美国多中心研究网络(TriNetX)提取2020年1月20日至2021年4月11日期间诊断为COVID-19的成人RA患者及无RA的成人COVID-19患者数据。
  • COVID-19结局评估时间为诊断后30天内,基线特征包括人口学和合并症通过倾向评分匹配控制。
  • 共纳入9730例RA合并COVID-19患者和656979例非RA的COVID-19患者。

主要发现

  • 匹配前RA组 vs 非RA组:死亡率RR 2.11(95%CI 1.90-2.34),住院RR 1.60(1.55-1.66),ICU入住RR 1.86(1.71-2.05),机械通气RR 1.62(1.44-1.82),重症COVID-19 RR 1.89(1.74-2.06),急性肾损伤RR 2.13(1.99-2.29),肾脏替代治疗/血液透析RR 1.40(1.03-1.89),ARDS RR 1.76(1.53-2.02),缺血性卒中RR 2.62(2.24-3.07),VTE RR 2.30(2.07-2.56),脓毒症RR 1.97(1.81-2.13)。
  • 匹配后RA组 vs 非RA组:VTE风险RR 1.18(95%CI 1.01-1.38),脓毒症风险RR 1.27(1.12-1.43),其余结局无差异。
  • 亚组分析:男性、黑人种族和糖皮质激素使用增加不良结局风险;利妥昔单抗或IL-6抑制剂使用者住院风险高于TNF抑制剂使用者,JAK抑制剂或阿巴西普使用者与TNF抑制剂使用者无显著差异。

临床怎么用

  • RA合并COVID-19患者应关注VTE和脓毒症风险,即使校正合并症后风险仍较高。
  • 男性、黑人种族及使用糖皮质激素的RA合并COVID-19患者可能需更密切监测。
  • 选择生物制剂时,利妥昔单抗或IL-6抑制剂使用者住院风险高于TNF抑制剂使用者,需权衡获益风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate outcomes of Coronavirus Disease-2019 (COVID-19) in patients with rheumatoid arthritis (RA) as compared to the general population. Additionally, outcomes were explored among RA patients stratified by sex, race, and medications use through sub-cohort analyses. METHODS: This comparative cohort study used a US multicenter research network (TriNetX) to extract data on all adult RA patients who were diagnosed with COVID-19, and adults without RA who were diagnosed with COVID-19 (comparative cohort) anytime from January 20, 2020 to April 11, 2021. COVID-19 outcomes were assessed within 30 days after its diagnosis. Baseline characteristics that included demographics and comorbidities were controlled in propensity score matching. RESULTS: A total of 9730 RA patients with COVID-19 and 656,979 non-RA with COVID-19 were identified. Before matching, the risk of all outcomes including mortality (RR: 2.11, 95%CI: 1.90 to 2.34), hospitalization (RR: 1.60, 1.55 to 1.66), intensive care unit-ICU admission (RR: 1.86, 1.71 to 2.05), mechanical ventilation (RR: 1.62, 1.44 to 1.82), severe COVID-19 (RR: 1.89, 1.74 to 2.06), acute kidney injury (RR: 2.13, 1.99 to 2.29), kidney replacement therapy/hemodialysis (RR: 1.40, 1.03 to 1.89), acute respiratory distress syndrome-ARDS (RR: 1.76, 1.53 to 2.02), ischemic stroke (RR: 2.62, 2.24 to 3.07), venous thromboembolism-VTE (RR: 2.30, 2.07 to 2.56), and sepsis (RR: 1.97, 1.81 to 2.13) was higher in RA compared to non-RA. After matching, the risks did not differ in both cohorts except for VTE (RR: 1.18, 1.01 to 1.38) and sepsis (RR: 1.27, 1.12 to 1.43), which were higher in the RA cohort. Male sex, black race, and glucocorticoid use increased the risk of adverse outcomes. The risk of hospitalization was higher in rituximab or interleukin 6 inhibitors (IL-6i) users compared to tumor necrosis factor inhibitors (TNFi) users, with no significant difference between Janus kinase inhibitors (JAKi) or abatacept users and TNFi users. CONCLUSION: This large cohort study of RA-COVID-19 found that the risk of all outcomes was higher in the RA compared to the non-RA cohort before matching, with no difference in the majority of outcomes after matching, implying the risk being attributed to adjusted factors. However, the risk of VTE and sepsis was higher in RA cohort even after matching, indicating RA as an independent risk factor. Male sex, black race, and glucocorticoid use were associated with adverse outcomes in RA with COVID-19. Rituximab or IL-6i users were associated with an increased risk of hospitalization compared to TNFi users.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Raiker R, DeYoung C, Pakhchanian H, et al. Outcomes of COVID-19 in patients with rheumatoid arthritis: A multicenter research network study in the United States. Semin Arthritis Rheum. 2021. PMID: 34450504. doi:10.1016/j.semarthrit.2021.08.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。